Impact Biomedical Announces U.S. Patent Allowance Of Laetose Technology Titled "Low Glycemic Sugar Composition"
Portfolio Pulse from Benzinga Newsdesk
Impact Biomedical has announced that it has received a U.S. patent allowance for its Laetose technology, which is a low glycemic sugar composition. This development could potentially offer a healthier alternative to traditional sugars, tapping into the growing market for health-conscious food ingredients.
January 30, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Document Security Systems, Inc. (DSS), which may be associated with Impact Biomedical, could see investor interest due to the patent allowance for Laetose technology, signaling potential growth in the health-conscious food sector.
The allowance of a U.S. patent for Laetose technology suggests that Impact Biomedical is making progress in the health-conscious food ingredients market. If DSS is indeed associated with Impact Biomedical, this could lead to increased investor confidence in DSS's potential for growth and innovation in this sector. The news is likely to be seen positively by the market, potentially leading to a short-term increase in DSS's stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 75